Frederic Cren, Inventiva CEO
Inventiva signs over China NASH rights to Sino Biopharm in possible $300M+ deal
More than two years after claiming a Phase II win in one of the most challenging diseases faced in biotech, Inventiva is handing over rights …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
